Dr. Navneet Singh

Dr. Navneet Singh
Pulmonologist, Chandigarh

MBBS, MD (Medicine), DM (Pulmonary Medicine and Critical Care)

  • 1 Hospital

Specialities

  • Pulmonology

Expertise

  • Thoracic Oncology (especially non-small cell lung cancer)

Education

MBBS, 1996, Govt Medical College, Chandigarh, India

MD (Medicine), 2001, CMC, Ludhiana, India

DM (Pulmonary Medicine and Critical Care), 2006, PGIMER, Chandigarh, India

Practice Information

Patient Experience

Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Navneet Singh and his staff know how they are doing and how they can improve their services.

Achievements & Contributions

  • Certificate of Appreciation for presenting high quality published research (among 10 best in Assistant Professor category) on 2nd Annual Research Day of PGIMER, Chandigarh in October 2013
  • Lung India Award for Prompt Referee by the Indian Chest Society (ICS) in 2013
  • Awarded Fellowship of the IndianChest Society (FICS) in 2011
  • Certificate of Appreciation for presenting high quality published research (among 10 best in Assistant Professor category) on 3rd Annual Research Day of PGIMER, Chandigarh in October 2014
  • Lung India Award for Prompt Referee by the Indian Chest Society (ICS) in 2014
  • Recipient of the International Development and Education Award (IDEA) of the American Society of Clinical Oncology (ASCO) for the year 2008
  • Awarded Fellowship of the American College of Chest Physicians  - FCCP in 2008
  • Travel grant from the European Society for Medical Oncology (ESMO) for presenting research paper and attending the European Multidisciplinary Congress in Thoracic Oncology at Lugano, Switzerland in May 2009
  • Selected by the American Association for Cancer Research (AACR) to be a recipient of the AACR-NCI International Investigator Opportunity Grant for the year 2009
  • Awarded Fellowship of the American College of Physicians  - FACP in 2010
  • Awarded Translational Research Unit (TRU) Visit Fellowship by the European Society for Medical Oncology (ESMO) in 2010. As part of this fellowship, attended the translational research in oncology course held at the University Medical Center, Groningen (UMCG), The Netherlands in March-April 2010
  • Travel scholarship from the Multinational Association of Supportive Care in Cancer (MASCC) for presenting research paper and attending the MASCC/ISOO International Symposium on Supportive Care in Cancer at Vancouver, British Columbia, Canada in June 2010
  • Scholarship for presenting research paper and attending the 15th World Conference on Tobacco Or Health (WCTOH) at Singapore in March 2012
  • Travel grant from the European Society for Medical Oncology (ESMO) for presenting research paper and attending the 3rd European Lung Cancer Conference at Geneva, Switzerland in April 2012
  • Awarded Palliative Care Research Fellowship of the European Society for Medical Oncology (ESMO) for the year 2012-2013. As part of this fellowship, visited the Kantonsspital, St Gallen, Switzerland in June-July 2013
  • Nominated as Member, Publications Committee, International Association for Study of Lung Cancer (IASLC) in October 2013
  • Travel grant from the European Society for Medical Oncology (ESMO) for attending the ESMO Symposium on Immuno-Oncology 2013 at Geneva, Switzerland in November 2013
  • Invited member of the International Development and Education Award (IDEA) Working Group of American Society of Clinical Oncology (ASCO) for a 3 year term (2014-17)
  • Singh N, Madan K, Aggarwal AN, Das A. Symptomatic large bilateral adrenal metastases at presentation in small-cell lung cancer : a case report and review of the literature. J Thorac Dis 2013; 5(3): E83-E86.
  • Agrawal K, Bhattacharya A, Singh N, Harisankar CN, Mittal BR. Skeletal muscle metastases as the initial manifestation of an unknown primary lung cancer detected on F-18 fluorodeoxyglucose positron emission tomography/computed tomography. Indian J Nucl Med 2013; 28(1): 34-35.
  • Singh N, Madan K, Aggarwal AN, Gupta N, Das A, Behera D. Pleuro-pulmonary tuberculosis following chemotherapy for lung cancer at a tertiary care centre in India. J Postgrad Med Edu Res 2013; 47(4): 177-180. (DOI : 10.5005/jp-journals-10028-1082
  • Bhagat P, Bal A, Das A, Singh N, Singh H. Pulmonary inflammatory myofibroblastic tumor and IgG4-related inflammatory pseudotumor: a diagnostic dilemma. Virchows Arch 2013; 463(6): 743-747.
  • Singh N, Behera D. Lung cancer epidemiology and clinical profile in North India: similarities and differences with other geographical regions of India. Indian J Cancer 2013; 50(4): 291.
  • Maturu VN, Singh N, Bansal P, Rai Mittal B, Gupta N, Behera D, Gupta A.Combination ofintravitreal bevacizumab and systemic therapy for choroidal metastases fromlung cancer: report of two cases and a systematic review of literature. Med Oncol. 2014; 31(4): 901.
  • Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions. Respir Care 2014; 59(5): 756-764.
  • Bhoil A, Singh B, Singh N, Kashyap R, Watts A, Sarika S, Mittal BR. Can 3'-deoxy-3'-18F-fluorothymidine or 2'-deoxy-2'-18F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results. Hell J Nucl Med. 2014; 17(2): 90-96.
  • Singh N, Behera D. Palliation in metastatic non-small cell lung cancer: Early integration with standard oncological care is the key. Lung India 2014; 31(4): 317-319.
  • Singh N, Vishwanath G, Aggarwal AN, Behera D. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash. Indian J Chest Dis Allied Sci 2014; 56(3): 149-152.
  • Singh N, Aggarwal AN, Kaur J, Behera D. Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of non-squamous NSCLC patients with pemetrexed based chemotherapy. Am J Clin Oncol DOI: 10.1097/COC.0000000000000111
  • Fellow of the American College of Chest Physicians (ACCP) 
  • Fellow of the American College of Physicians (ACP)
  • American Society of Clinical Oncology (ASCO)
  • European Society for Medical Oncology (ESMO)
  • International Association for the Study of Lung Cancer (IASLC)
  • American Association for Cancer Research (AACR)
  • European Respiratory Society (ERS)
  • American Thoracic Society (ATS)
  • International Union Against Tuberculosis and Lung Disease (IUATLD)
  • Fellow of the Indian Chest Society (ICS) - FICS
  • Indian Society for Study of Lung Cancer (ISSLC)
  • National College of Chest Physicians (India) NCCP (I)
  • Indian Society of Critical Care Medicine (ISCCM)
  • Indian Association for Bronchology (IAB)